A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy‐free approach in HER2‐positive metastatic breast cancer: The HAT study (BOOG 2008‐2003), a Dutch Breast Cancer Research Group trial

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|122|19|2961-2970

ISSN： 0008-543x

Source： CANCER, Vol.122, Iss.19, 2016-10, pp. : 2961-2970

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Herceptin® Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials

By  

Oncology, Vol. 61, Iss. 2, 2001-10 ,pp. : 14-21

Karger

Access to resources Recommend Favorite

Is Gemcitabine plus Vinorelbine Active in Second-Line Chemotherapy of Metastatic Breast Cancer? A Single-Center Phase 2 Study

By  

Oncology, Vol. 64, Iss. 4, 2003-05 ,pp. : 479-480

Karger

Access to resources Recommend Favorite

Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 33, Iss. 8-9, 2010-07 ,pp. : 420-421

Karger

Access to resources Recommend Favorite

Adjuvant Chemotherapy for the Treatment of HER2-Positive Early Breast Cancer

By  

Oncology, Vol. 77, Iss. 1, 2010-02 ,pp. : 14-17

Karger

Access to resources Recommend Favorite

A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 129-135

Karger

Access to resources Recommend Favorite